Therapeutic Potential of MgH2 in Mitigating Cisplatin-Induced Hearing Loss
Neuroscience Bulletin · 2026
DOI: 10.1007/s12264-025-01477-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroscience Bulletin, 2026. Verfasst von Yibing Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, …. Hauptthemen laut MEDLINE: Cisplatin, Hearing Loss, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cisplatin is a widely-used chemotherapeutic agent, but its dose-limiting ototoxicity often results in irreversible hearing loss. The pathogenesis involves oxidative stress, apoptosis, DNA damage, and inflammatory responses, yet effective preventive strategies remain limited. Here, we demonstrate that magnesium hydride (MgH2), a hydrogen-releasing compound, provides robust protection against cisplatin-induced hearing loss. Our results showed that MgH2 protected auditory function and preserved cochlear hair cells in vivo. Furthermore, it significantly attenuated cisplatin-induced oxidative stress and apoptosis in cultured HEI-OC1 (House Ear Institute-Organ of Corti 1) cells and cochlear explants. Notably, MgH2 suppressed NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated inflammatory cascades, thereby limiting downstream inflammatory damage. These findings revealed that MgH2 alleviated cisplatin-induced hearing loss through integrated antioxidant, anti-inflammatory, and anti-apoptotic pathways, with NLRP3 identified as a critical regulatory molecule. Collectively, our study provides compelling evidence for MgH2 as a potential therapeutic candidate for the prevention of cisplatin-induced hearing loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
- Shanghai Key Laboratory of Sleep Disordered Breathing, Otolaryngology Institute of Shanghai Jiao Tong University, Shanghai, 200233, China.
- Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
- Department of Otolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China. yazhi_0807@hotmail.com.
- Shanghai Key Laboratory of Sleep Disordered Breathing, Otolaryngology Institute of Shanghai Jiao Tong University, Shanghai, 200233, China. yazhi_0807@hotmail.com.
- Department of Otolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China. jassey@126.com.
Zitieren
APA
Hu, Y., Zhang, Y., Li, S., Yu, Y., Wang, J., Lou, Z., Zhang, B., Xing, Y., & Chen, Z. (2026). Therapeutic Potential of MgH2 in Mitigating Cisplatin-Induced Hearing Loss. Neuroscience Bulletin. https://doi.org/10.1007/s12264-025-01477-2
Vancouver
Hu Y, Zhang Y, Li S, Yu Y, Wang J, Lou Z, et al. Therapeutic Potential of MgH2 in Mitigating Cisplatin-Induced Hearing Loss. Neuroscience Bulletin. 2026. doi:10.1007/s12264-025-01477-2
BibTeX
@article{Hu2026,
author = {Hu, Yibing and Zhang, Yihuan and Li, Shufen and Yu, Yuan and Wang, Jingjing and Lou, Zihan and Zhang, Boya and Xing, Yazhi and Chen, Zhengnong},
title = {Therapeutic Potential of MgH2 in Mitigating Cisplatin-Induced Hearing Loss},
journal = {Neuroscience Bulletin},
year = {2026},
doi = {10.1007/s12264-025-01477-2}
}
EUVIMED